The Accuracy of 3-D Inhomogeneity Photon Algorithms in Commercial Treatment Planning Systems using a Heterogeneous Lung Phantom

Gary Fisher, B.S.

David Followill, Ph.D.

Geoffrey Ibbott, Ph.D.



This investigation was supported by PHS grant CA10953 awarded by the NCI, DHHS.





Introduction

- Simple density-correction algorithms have insufficient accuracy within the lungs
- Previous studies of lung density corrections
 - based on slab phantoms
 - simple beam geometries
- Current generation convolution based algorithms should provide better dose estimates
- Limited data is available verifying the accuracy in an anthropomorphic phantom
- Differences between implementations of heterogeneity correction algorithms needs to be quantified before applying them in multi-institutional clinical trials

Objectives

- Quantify the differences between heterogeneous dose estimates from the calculation algorithms of three 3-D treatment planning systems and dosimetry measurements.

 - Varian Eclipse
 - CMS XiO

– Philips Pinnacle³ (Collapsed Cone Convolution) (Pencil Beam with 1/D correction) (MultiGrid Superposition)

(Clarkson with 1/D correction)

- Develop clinically constrained conformal treatment plans for lung inserts with a centrally and medially located tumor.
- Measure dose distributions delivered by these treatments.
- Compare measured and calculated dose distributions based on the TG-53 criteria of $\pm 5\%/3$ mm.

Methods and Materials

- RPC's Anthropomorphic Thorax Phantom
 - Simulated heart, spine,
 lungs, and lung tumor
 heterogeneities
 - Tumor located centrally, or toward anterior mediastinum
 - TLD (Tumor, Heart, Cord)
 - Radiochromic film (Axial, Coronal, and Sagittal)





Methods and Materials

- Conformal Treatment Plans
 - Clinically constrained prescriptions
 - Limited to four fields
 - 6 MV or 18 MV plans
 - 20Gy to prescription point
- Dosimetric evaluation criteria
 - 5% or 3mm distance to agreement (TG-53)
 - Relaxed constraint level were investigated to 7%/7mm





Methods and Materials

- Dosimeters
 - TLD's for absolute dose in tumor (superior and inferior), heart, and cord. Corrected for measured output and calibration differences.
 - Radiochromic Film for 2-D dose distributions (axial, sagittal, coronal) and profiles. Converted from OD to Dose. Films were normalized to the TLD dose.
 - Film localization was based on registration pinholes.
 - Dosimetry reproducibility evaluation 3 irradiations.

TLD Results Measured / Calculated

Plan / Energy	Pinnacle	XiO MGS	Eclipse	XiO Clarkson
Center 6 MV	1.022	0.981	0.957	0.925
Offset 6 MV	1.017	0.978	0.965	0.919
Offset 18 MV	1.038	1.030	1.012	0.960







Pinnacle Profile Results

Average profile from normalized film and Pinnacle calculated profile comparison for the offset tumor plans



The display on the right shows binary agreement map results from 5%/3mm – 7%/7mm

Pinnacle 2-D Results for 6 MV Offset





The display on the right shows binary agreement map results from 5%/3mm – 7%/7mm

Pinnacle 2-D Results for 18 MV Offset







XiO MGS Profile Results

Average profile from normalized film and Eclipse calculated profile comparison for the offset tumor plans



The display on the right shows binary agreement map results from 5%/3mm – 7%/7mm

XiO MGS 2-D Results for 6 MV Offset







Eclipse Profile Results

Average profile from normalized film and Eclipse calculated profile comparison for the offset tumor plans



The display on the right shows binary agreement map results from 5%/3mm – 7%/7mm

Eclipse 2-D Results for 6 MV Offset







XiO Clarkson Profile Results

Average profile from normalized film and Eclipse calculated profile comparison for the offset tumor plans



The display on the right shows binary agreement map results from 5%/3mm – 7%/7mm

XiO Clarkson 2-D Results for 6 MV Offset



Results - Binary Comparison



Conclusions

- Pinnacle and XiO's MGS provide clinically acceptable results
- Pinnacle and XiO's MGS could be compared directly in clinical trial settings
- Eclipse does not account for the increased lateral range of secondary particles
- XiO's Clarkson overestimates the dose ~10% throughout the PTV

Acknowledgements

- Michele Ferenci, Ph.D. Elizabeth Butker, M.S.
 - The Emory Clinic, Atlanta, GA.
- Christopher Dennett, M.S. Gwen Barnhart, C.M.D.
 - Memorial Hospital, Colorado Springs, CO.
- Naresh Tolani, M.S.
 - M.D. Anderson Cancer Center, Houston, TX.
- Bryan Stewart
 - Radiological Physics Center, Houston, TX.



